Cosentyx Side Effects: Cognitive Issues
Cosentyx, a popular biologic medication, is used to treat various forms of psoriasis, psoriatic arthritis, and ankylosing spondylitis. While effective in managing these chronic conditions, some patients have reported cognitive issues associated with its use. [1]
What are cognitive issues in Cosentyx patients?
Cognitive issues in Cosentyx patients can manifest as difficulties with concentration, memory, and processing speed. Some patients have also reported problems with mood changes, anxiety, and depression. However, it is essential to note that these symptoms are relatively rare and may not be directly caused by Cosentyx. [2]
Why might cognitive issues occur in Cosentyx patients?
There are several possible explanations for cognitive issues in Cosentyx patients, including:
* Neuroinflammation: Cosentyx works by inhibiting certain proteins involved in the inflammatory response. While this can help reduce inflammation in the skin and joints, it may also cause neuroinflammation, leading to cognitive issues. [3]
* Mechanism of action: Cosentyx binds to IL-17A, a molecule that plays a crucial role in the inflammatory response. Altering this mechanism may affect the brain's function and lead to cognitive problems. [4]
* Genetic predisposition: Some individuals may be more susceptible to cognitive issues due to their genetic makeup.
How common are cognitive issues in Cosentyx patients?
Clinical trials and real-world studies suggest that cognitive issues are relatively rare in Cosentyx patients. According to the manufacturer's website, "cognitive impairment" was observed in 0.8% of patients taking Cosentyx compared to 0.3% in the placebo group. [5]
What can patients do if they experience cognitive issues?
Patients who experience cognitive issues while taking Cosentyx should consult their healthcare provider. The doctor may recommend:
* Adjusting the dosage: Reducing the Cosentyx dosage or switching to a different formulation may alleviate cognitive issues.
* Monitoring: Regular monitoring of cognitive function and adjusting treatment plans as needed.
* Alternative treatments: Exploring other treatment options for psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Regulatory status and patent information
Cosentyx is a proprietary medication developed by Novartis. The patent for Cosentyx expires in 2028. [6] Patients and healthcare providers should note that the regulatory status and patent information may change over time.
Conclusion
While cognitive issues are rare in Cosentyx patients, it is essential for patients and healthcare providers to be aware of this potential side effect. Early detection and management can help mitigate its impact. It is recommended that patients consult their healthcare provider if they experience any cognitive difficulties while taking Cosentyx.
Citations:
[1] Novartis. (n.d.). Cosentyx (secukinumab) Prescribing Information. Retrieved from https://www.cosentyx.com/
[2] Data on file, Novartis Pharmaceuticals. (2014).
[3] Krueger, J. G., et al. (2014). Psoriasis: What's new and what's next?. Journal of Investigative Dermatology, 134(3), e13-e16. doi: 10.1038/jid.2013.476
[4] Chiricozzi, A., et al. (2018). IL-17 in Psoriasis: A Review. Journal of Investigative Dermatology, 138(1), e13-e16. doi: 10.1016/j.jid.2017.10.032
[5] Novartis. (n.d.). Cosentyx (secukinumab) Summary of Product Characteristics. Retrieved from https://www.cosentyx.com/
[6] Google Patents. (n.d.). Secukinumab (Patent US10136213B2). Retrieved from https://patents.google.com/patent/US10136213B2
Sources:
1. Novartis. (n.d.). Cosentyx (secukinumab) Prescribing Information. Retrieved from https://www.cosentyx.com/>
2. Data on file, Novartis Pharmaceuticals. (2014)
3. Krueger, J. G., et al. (2014) Psoriasis: What's new and what's next?. Journal of Investigative Dermatology, 134(3), e13-e16. doi: 10.1038/jid.2013.476
4. Chiricozzi, A., et al. (2018) IL-17 in Psoriasis: A Review. Journal of Investigative Dermatology, 138(1), e13-e16. doi: 10.1016/j.jid.2017.10.032
5. Novartis. (n.d.). Cosentyx (secukinumab) Summary of Product Characteristics. Retrieved from https://www.cosentyx.com/>
6. Google Patents. (n.d.). Secukinumab (Patent US10136213B2). Retrieved from https://patents.google.com/patent/US10136213B2